ALVAC-HIV (vCP1521)

AXP000202.1 · Vaccine

Platform
canarypox (ALVAC)
Targets
HIV-1 CRF01_AE gp120; HIV-1 Gag; HIV-1 protease
Originator
Virogenetics / Aventis Pasteur
Sponsor
Sanofi Pasteur

Names

NameTypeSource
ALVAC-HIV (vCP1521)preferred namecurator
ALVAC-HIV vCP1521codepaper
vCP1521codepaper

Virus

Role
Vaccine vector
Family
Poxviridae
Virus
canarypox virus (NCBI Taxonomy 44088)
Strain
ALVAC (vCP1521)
Replication
non replicating
Modifications
HIV-1 CRF01_AE (92TH023) env gp120 with clade B LAI gp41 anchor, plus LAI gag and protease
Transgenes
HIV-1 env gp120 (CRF01_AE 92TH023), HIV-1 gag (LAI), HIV-1 protease (LAI)
Source
evidence

Approvals

No regulatory approval recorded.

Clinical trials (4)

TrialTitleStatusPhaseStartPrimary completionEnrolmentConditions
NCT02109354Safety of and Immune Response to Vaccination With 2 Experimental HIV Vaccines in Healthy AdultsCompletedPhase 12013-06-182015-02-02202HIV Infection
NCT01435135Study of Late Boost Strategies for HIV-uninfected Participants From Protocol RV 144UnknownPhase 22012-042021-07162HIV Infections
NCT00223080HIV Vaccine Trial in Thai AdultsCompletedPhase 32003-102006-0716402HIV Infection
NCT00098163Safety of and Immune Response to an HIV-1 Vaccine (ALVAC-HIV vCP1521) in Infants Born to HIV Infected MothersCompletedPhase 160HIV Infections

Recent changes

No changes recorded in its trials yet.

Clinical papers

PubMedTitleJournalYearLinked by
PMID 40190112A polyvalent DNA prime with matched polyvalent protein/GLA-SE boost regimen elicited the most robust and broad IgG and IgG3 V1V2 binding antibody and CD4+ T cell responses among 13 HIV vaccine trials.Emerging microbes & infections2025cited by trial NCT00223080
PMID 37256916Viral vector delivered immunogen focuses HIV-1 antibody specificity and increases durability of the circulating antibody recall response.PLoS pathogens2023cited by trial NCT00223080
PMID 31999736Landscapes of binding antibody and T-cell responses to pox-protein HIV vaccines in Thais and South Africans.PloS one2020cited by trial NCT00223080
PMID 32035516Late boosting of the RV144 regimen with AIDSVAX B/E and ALVAC-HIV in HIV-uninfected Thai volunteers: a double-blind, randomised controlled trial.The lancet. HIV2020name in abstract: ALVAC-HIV vCP1521
PMID 29702672Characterization of HIV-1 gp120 antibody specificities induced in anogenital secretions of RV144 vaccine recipients after late boost immunizations.PloS one2018cited by trial NCT00223080
PMID 28131393Predictors of durable immune responses six months after the last vaccination in preventive HIV vaccine trials.Vaccine2017cited by trial NCT00223080
PMID 28235027Boosting of HIV envelope CD4 binding site antibodies with long variable heavy third complementarity determining region in the randomized double blind RV305 HIV-1 vaccine trial.PLoS pathogens2017cited by trial NCT01435135
PMID 28329190Randomized, Double-Blind Evaluation of Late Boost Strategies for HIV-Uninfected Vaccine Recipients in the RV144 HIV Vaccine Efficacy Trial.The Journal of infectious diseases2017cited by trial NCT01435135
PMID 26234467IgG Antibody Responses to Recombinant gp120 Proteins, gp70V1/V2 Scaffolds, and a CyclicV2 Peptide in Thai Phase I/II Vaccine Trials Using Different Vaccine Regimens.AIDS research and human retroviruses2015name in abstract: ALVAC-HIV vCP1521
PMID 24091694Immunogenicity of ALVAC-HIV vCP1521 in infants of HIV-1-infected women in Uganda (HPTN 027): the first pediatric HIV vaccine trial in Africa.Journal of acquired immune deficiency syndromes (1999)2014cited by trial NCT00098163
PMID 24504509Vaccine-induced IgG antibodies to V1V2 regions of multiple HIV-1 subtypes correlate with decreased risk of HIV-1 infection.PloS one2014cited by trial NCT00223080
PMID 24829343Analysis of HLA A*02 association with vaccine efficacy in the RV144 HIV-1 vaccine trial.Journal of virology2014cited by trial NCT00223080
PMID 25350851CD8 and CD4 epitope predictions in RV144: no strong evidence of a T-cell driven sieve effect in HIV-1 breakthrough sequences from trial participants.PloS one2014cited by trial NCT00223080
PMID 25401780Uptake of genital mucosal sampling in HVTN 097, a phase 1b HIV vaccine trial in South Africa.PloS one2014cited by trial NCT02109354
PMID 23221981Feasibility and safety of ALVAC-HIV vCP1521 vaccine in HIV-exposed infants in Uganda: results from the first HIV vaccine trial in infants in Africa.Journal of acquired immune deficiency syndromes (1999)2013cited by trial NCT00098163
PMID 22529301The Thai phase III trial (RV144) vaccine regimen induces T cell responses that preferentially target epitopes within the V2 region of HIV-1 envelope.Journal of immunology (Baltimore, Md. : 1950)2012name in abstract: ALVAC-HIV vCP1521
PMID 22634875Magnitude and breadth of the neutralizing antibody response in the RV144 and Vax003 HIV-1 vaccine efficacy trials.The Journal of infectious diseases2012name in abstract: vCP1521
PMID 22652344Risk behaviour and time as covariates for efficacy of the HIV vaccine regimen ALVAC-HIV (vCP1521) and AIDSVAX B/E: a post-hoc analysis of the Thai phase 3 efficacy trial RV 144.The Lancet. Infectious diseases2012name in title: ALVAC-HIV vCP1521
PMID 23035746The Thai Phase III HIV Type 1 Vaccine trial (RV144) regimen induces antibodies that target conserved regions within the V2 loop of gp120.AIDS research and human retroviruses2012name in abstract: ALVAC-HIV vCP1521
PMID 22205930Safety and reactogenicity of canarypox ALVAC-HIV (vCP1521) and HIV-1 gp120 AIDSVAX B/E vaccination in an efficacy trial in Thailand.PloS one2011cited by trial NCT00223080
PMID 19843557Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand.The New England journal of medicine2009cited by trial NCT00223080
PMID 17909315A phase 1/2 comparative vaccine trial of the safety and immunogenicity of a CRF01_AE (subtype E) candidate vaccine: ALVAC-HIV (vCP1521) prime with oligomeric gp160 (92TH023/LAI-DID) or bivalent gp120 (CM235/SF2) boost.Journal of acquired immune deficiency syndromes (1999)2007name in title: ALVAC-HIV vCP1521
PMID 16910837Molecular epidemiology of HIV Type 1 in preparation for a Phase III prime-boost vaccine trial in Thailand and a new approach to HIV Type 1 genotyping.AIDS research and human retroviruses2006name in abstract: ALVAC-HIV vCP1521
PMID 15752839Antibody-dependent cell-mediated cytotoxic responses in participants enrolled in a phase I/II ALVAC-HIV/AIDSVAX B/E prime-boost HIV-1 vaccine trial in Thailand.Vaccine2005name in abstract: ALVAC-HIV vCP1521
PMID 15242541Enhanced sensitivity of detection of cytotoxic T lymphocyte responses to HIV type 1 proteins using an extended in vitro stimulation period for measuring effector function in volunteers enrolled in an ALVAC-HIV phase I/II prime boost vaccine trial in Thailand.AIDS research and human retroviruses2004name in abstract: ALVAC-HIV vCP1521
PMID 15272397Safety and immunogenicity of an HIV subtype B and E prime-boost vaccine combination in HIV-negative Thai adults.The Journal of infectious diseases2004name in abstract: ALVAC-HIV vCP1521

Other papers

Preclinical studies, reviews and other papers that name it.

PubMedTitleJournalYearLinked by
PMID 31566582Simplified steps to heterologous prime-boost HIV vaccine development?The Journal of clinical investigation2019name in abstract: vCP1521
PMID 28645240Engineered Expression of Broadly Neutralizing Antibodies Against Human Immunodeficiency Virus.Annual review of virology2017name in abstract: ALVAC-HIV vCP1521
PMID 28678869V1V2-specific complement activating serum IgG as a correlate of reduced HIV-1 infection risk in RV144.PloS one2017name in abstract: vCP1521
PMID 26041302Head-to-Head Comparison of Poxvirus NYVAC and ALVAC Vectors Expressing Identical HIV-1 Clade C Immunogens in Prime-Boost Combination with Env Protein in Nonhuman Primates.Journal of virology2015name in abstract: vCP1521
PMID 24648341Polyfunctional Fc-effector profiles mediated by IgG subclass selection distinguish RV144 and VAX003 vaccines.Science translational medicine2014name in abstract: ALVAC-HIV vCP1521
PMID 22992109Short communication: evaluating the level of expressed HIV type 1 gp120 and gag proteins in the vCP1521 vector by two immunoplaque methods.AIDS research and human retroviruses2013name in title: vCP1521
PMID 23209178Human immunodeficiency virus vaccine trials.Cold Spring Harbor perspectives in medicine2012name in abstract: ALVAC-HIV vCP1521
PMID 20711452Comparative immunogenicity of HIV-1 clade C envelope proteins for prime/boost studies.PloS one2010name in abstract: vCP1521
PMID 12757073Evaluation of attitude, risk behavior and expectations among Thai participants in Phase I/II HIV/AIDS vaccine trials.Journal of the Medical Association of Thailand = Chotmaihet thangphaet2003name in abstract: ALVAC-HIV vCP1521
PMID 12848591HIV gp120 vaccine - VaxGen: AIDSVAX, AIDSVAX B/B, AIDSVAX B/E, HIV gp120 vaccine - Genentech, HIV gp120 vaccine AIDSVAX - VaxGen, HIV vaccine AIDSVAX - VaxGen.Drugs in R&D2003name in abstract: ALVAC-HIV vCP1521
PMID 11495295Cytotoxic T lymphocyte responses to vaccinia virus antigens but not HIV-1 subtype E envelope protein seen in HIV-1 seronegative Thais.Asian Pacific journal of allergy and immunology2001name in abstract: vCP1521

NIH grants

ProjectTitleOrganisationPIYearsLinked by
U19AI109646Cellular ResponsesWISTAR INSTITUTEWEINER, DAVID B.2015–2019name in abstract: vCP1521
R01AI091450Modulation of HIV-specific CD8+ T and B cell function by CD4+ T helper responsesHENRY M. JACKSON FDN FOR THE ADV MIL/MEDSTREECK, HENDRIK2010–2013name in abstract: ALVAC-HIV vCP1521
R21AI096949T-follicular helper cells in Env-immunized macaquesUNIVERSITY OF MARYLAND BALTIMOREPAUZA, C. DAVID2012–2013name in abstract: vCP1521

Notes

Canarypox vector vCP1521 carrying HIV-1 clade AE (92TH023) env gp120 anchored by a clade B LAI gp41 segment, plus clade B LAI gag and protease. Prime in the phase 3 RV144 trial in Thailand (>16,000 volunteers, US Army/Thai MoPH), boosted with the AIDSVAX B/E protein: 31.2% efficacy in the modified intent-to-treat analysis, reported 2009. The protein boost is a separate, non-viral product. Route (intramuscular) not confirmed from the pages opened.

How to cite

ALVAC-HIV (vCP1521) (AXP000202.1). The Abstractinator program registry, release 2026-11-17+2c46e992acfc. https://abstractinator.me/registry/AXP000202.html

Something wrong or missing? Suggest a correction (a GitHub issue; please link your evidence). Entry created 2026-11-11, updated 2026-11-11.